{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:23:53Z","timestamp":1793762633419,"version":"4.6.1"},"reference-count":29,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Follicular lymphoma (FL) and marginal zone lymphoma (MZL) often have long overall survival (OS), however, high-grade transformation (HGT) to diffuse large B-cell lymphoma markedly reduces survival. The roles of upfront treatment vs observation on the incidence and outcome of HGT remain unclear. Thus, we analyzed a Surveillance, Epidemiology, and End Results database to address this question. Patients diagnosed with FL grades 1 to 2 or MZL between 2000 and 2020 were included. Fine-Gray models estimated the impact of covariates on HGT cumulative incidence and lymphoma-specific survival (LSS) and Cox regression on OS. HGT occurred in 4.2% of 23\u2009384 patients with FL and 2.5% of 20\u2009530 patients with MZL. The 5- and 10-year HGT cumulative incidence rates were 2.80% and 4.87% for FL, and 1.74% and 2.95% for MZL, respectively, which are notably lower than in earlier studies. The annual HGT incidence rate peaked in the first 2 years, then steadily declined over 2 decades for FL and all MZL subtypes. In FL, upfront observation vs treatment increases HGT risk (sub-distribution hazard ratio [SHR], 1.23; 95% confidence interval [CI], 1.09-1.40; P\u00a0&amp;lt; .001) and barely affects OS (hazard ratio [HR], 0.95; 95%\u00a0CI, 0.90-0.99; P\u00a0=\u00a0.03). Conversely, upfront observation was associated with lower HGT risk in nodal (SHR, 0.71; 95%\u00a0CI, 0.53-0.94; P\u00a0=\u00a0.01) and extranodal (SHR, 0.64; 95%\u00a0CI, 0.48-0.86; P\u00a0=\u00a0.003) MZL and did not affect survival in extranodal disease (HR, 0.94; 95%\u00a0CI, 0.97-1.02; P\u00a0=\u00a0.15). HGT was associated with decrease in LSS across all histologies. Upfront treatment reduced the risk of HGT only in FL but not MZL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013499","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T21:19:52Z","timestamp":1719955192000},"page":"4423-4432","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Risk of transformation by frontline management in follicular and marginal zone lymphomas: a US population\u2013based analysis"],"prefix":"10.1182","volume":"8","author":[{"given":"Jorge A.","family":"Florindez","sequence":"first","affiliation":[{"name":"1Division of Hematology, The University of North Carolina Chapel Hill, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-2294","authenticated-orcid":false,"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[{"name":"2Department of Lymphoma & Myeloma, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isildinha M.","family":"Reis","sequence":"additional","affiliation":[{"name":"3Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL"},{"name":"4Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-3377","authenticated-orcid":false,"given":"Juan Pablo","family":"Alderuccio","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"issue":"6","key":"2024082713061010800_bib1","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2024082713061010800_bib2","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/annonc\/mdv368","article-title":"Histologic transformation in marginal zone lymphomas\u2020","volume":"26","author":"Conconi","year":"2015","journal-title":"Ann Oncol"},{"key":"2024082713061010800_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.humpath.2020.06.001","article-title":"Non\u2013diffuse large B-cell lymphoma transformation from follicular lymphoma: a single-institution study of 19 cases","volume":"102","author":"Maeshima","year":"2020","journal-title":"Hum Pathol"},{"issue":"4","key":"2024082713061010800_bib4","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2024082713061010800_bib5","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"2024082713061010800_bib6","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2008.16.0283","article-title":"Population-based analysis of incidence and outcome of transformed non-Hodgkin\u2019s lymphoma","volume":"26","author":"Al-Tourah","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2024082713061010800_bib7","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2024082713061010800_bib8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","article-title":"Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS)","volume":"126","author":"Wagner-Johnston","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2024082713061010800_bib9","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol"},{"issue":"2","key":"2024082713061010800_bib10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/annonc\/mds433","article-title":"Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy","volume":"24","author":"Bains","year":"2013","journal-title":"Ann Oncol"},{"issue":"34","key":"2024082713061010800_bib11","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1200\/JCO.18.00138","article-title":"Risk factors for transformation to higher-grade lymphoma and its impact on survival in a large cohort of patients with marginal zone lymphoma from a single institution","volume":"36","author":"Alderuccio","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024082713061010800_bib12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024082713061010800_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal zone lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann Oncol"},{"issue":"4","key":"2024082713061010800_bib14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10","key":"2024082713061010800_bib15","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdl162","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma","volume":"17","author":"Gin\u00e9","year":"2006","journal-title":"Ann Oncol"},{"issue":"2","key":"2024082713061010800_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1365-2141.2012.09054.x","article-title":"Incidence, risk factors and outcome of histological transformation in follicular lymphoma","volume":"157","author":"Conconi","year":"2012","journal-title":"Br J Haematol"},{"issue":"22","key":"2024082713061010800_bib17","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","article-title":"Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial","volume":"34","author":"Sarkozy","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"2024082713061010800_bib18","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program\n          . SEER\u2217Stat Databases: Incidence - SEER Research Data, 17 Registries, Nov 2022 Sub (2000-2020) - Linked to County attributes - Time Dependent (1990-2021) Income\/Rurality, 1969-2021 Counties. National Cancer Institute, DCCPS, Surveillance Research Program; released April 2023. Accessed 3 January 2024. https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2022\/."},{"issue":"446","key":"2024082713061010800_bib19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2024082713061010800_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/978-3-642-48425-4_2","volume-title":"Statistical Theory and Computational Aspects of Smoothing","author":"Cleveland","year":"1996"},{"issue":"7","key":"2024082713061010800_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.21037\/atm.2018.02.12","article-title":"Time-varying covariates and coefficients in Cox regression models","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann Transl Med"},{"issue":"2 Pt 1","key":"2024082713061010800_bib22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/1078-0432.CCR-06-1210","article-title":"Cumulative incidence in competing risks data and competing risks regression analysis","volume":"13","author":"Kim","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2024082713061010800_bib23","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00277-017-3218-0","article-title":"The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database","volume":"97","author":"Janikova","year":"2018","journal-title":"Ann Hematol"},{"issue":"6","key":"2024082713061010800_bib24","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00277-015-2303-5","article-title":"Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis","volume":"94","author":"Lerch","year":"2015","journal-title":"Ann Hematol"},{"issue":"3","key":"2024082713061010800_bib25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood-2017-03-691345","article-title":"Can histologic transformation of follicular lymphoma be predicted and prevented?","volume":"130","author":"Kridel","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2024082713061010800_bib26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41408-023-00831-9","article-title":"Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study","volume":"13","author":"Kalashnikov","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"2024082713061010800_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41408-023-00903-w","article-title":"A\u00a0population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics","volume":"13","author":"Bult","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"2024082713061010800_bib28","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood.V95.6.1950","article-title":"Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients","volume":"95","author":"Berger","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2024082713061010800_bib29","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/annonc\/mdt507","article-title":"Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma","volume":"25","author":"Meyer","year":"2014","journal-title":"Ann Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4423\/2239687\/blooda_adv-2024-013499-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4423\/2239687\/blooda_adv-2024-013499-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T13:06:36Z","timestamp":1724763996000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/16\/4423\/516830\/Risk-of-transformation-by-frontline-management-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":29,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013499","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]}}}